EP1256000A2 - Verfahren zur diagnose bilio-pankreatischer karzinome - Google Patents
Verfahren zur diagnose bilio-pankreatischer karzinomeInfo
- Publication number
- EP1256000A2 EP1256000A2 EP01903698A EP01903698A EP1256000A2 EP 1256000 A2 EP1256000 A2 EP 1256000A2 EP 01903698 A EP01903698 A EP 01903698A EP 01903698 A EP01903698 A EP 01903698A EP 1256000 A2 EP1256000 A2 EP 1256000A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- pancreatic
- bilio
- activating peptide
- tap
- diagnosis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
Definitions
- the invention relates to a method for diagnosing diseases of the bilio-pancreatic system, in particular carcinomas, and claims the priority of German patent application 100 04 919, to which reference is made in terms of content.
- the organs of the so-called bilio-pancreatic system namely the pancreas, the gallbladder with the bile ducts, and the papilla vateri as the common mouth of the coledochal duct leading from the liver and the gallbladder and the duct of the pancreatic duct leading from the pancreas Duodenum, arise during embryogenesis from a bud of the duodenum system.
- Malignant tumors can develop in these organs, which - with increasing incidence - represent a common cause of death for humans. Every fourth death due to malignant neoplasms is due to pancreatic cancer (pancreatic cancer).
- FIG. 1 shows the characteristic age distribution of the incidence of pancreatic cancer.
- the Bile duct carcinoma is still the fifth most common cause of cancer-related deaths.
- papillary cancer i.e. of the Papilla Vateri tumor
- carcinomas of the bilio-pancreatic system have in common that they are due to less specific symptoms such as a general decrease in performance, weight loss, or painless symptoms - e.g. Painless jaundice (jaundice) - can only be diagnosed late and therefore only recognized late.
- papillary cancer can be recognized earlier. This exceptional position of papillary carcinoma may be due to the exposed anatomical position of the papilla Vateri, which causes the symptoms that are conspicuous at an early stage in the formation of a tumor and thus allows a quicker diagnosis and better prognosis.
- pancreatic carcinoma the so-called screening of carcinomas.
- this is due to the often unspecific fishing or painless symptoms very difficult.
- pancreatic carcinoma the difficulty of differentiating between the pancreatic carcinoma and chronic pancreatitis, since both pancreatic diseases show similar clinical symptoms.
- a distinction can often not be made even after surgery and a pathohistological examination and can only be assessed on the basis of the further clinical course (death / survival).
- the dignity assessment i.e. The differentiation between an inflammatory benign and a malignant pancreatic disease is also important because of the suspected - but not yet finally confirmed - causal relationship between chronic pancreatitis and the pathogen of pancreatic cancer. Studies have shown that hereditary pancreatitis carries a standardized risk of degeneration of 53.
- carcinoma of the bile duct or gallbladder is often associated with chronic inflammatory bowel disease (ulcerative colitis).
- gallstones which in turn can trigger chronic inflammation.
- the object of the invention is to provide a method for the early detection of carcinomas of the bilio-pancreatic system.
- the invention is based on the idea of quantifying the trypsinogen-activating peptide (hereinafter TAP) in the body's own fluids to detect malignant tumors in the bilio-pancreatic system. Accordingly, the method according to the invention is based on the function of an increased TAP concentration as a marker for bilipancreatic carcinomas and thus presupposes a connection between an increased TAP concentration and the occurrence of malignant tumors.
- TAP trypsinogen-activating peptide
- the trypsinogen is formed in the pancreas as an inactive precursor (zymogen) of the protein-digesting enzyme trypsin.
- the trypsinogen is secreted into the duodenum via the pancreatic duct at the common mouth with the coledochus duct coming from the gallbladder and liver. This is where the trypsinogen in trypsin is activated by the hydrolytically active enterokinase (enteropeptidase) produced in the intestinal mucosa.
- trypsinogen-activating peptide (TAP) due to its trypsinogen-activating property.
- TAP trypsinogen-activating peptide
- This previously recognized model thus attributes acute pancreatitis to the backflow of bile juice into the pancreas, which in some cases is associated with zymogen activation.
- a connection between the zymogen activation and the pathogenesis of gallbladder and biliary tract inflammation as well as corresponding carcinomas is excluded because - according to the model - the pancreatic juice containing the zymogens does not come into contact with these organs. The same applies to papillary cancer.
- pancreatic cancer does not involve activation of the zymogens contained in the pancreas. This also applies to the hydrolysis of the trypsinogen to active trypsin and TAP.
- TAP is suitable as an indicator of the presence of bilio-pancreatic carcinomas.
- the teaching according to the invention thus initially requires a departure from the long-recognized theory.
- the teaching according to the invention is based on the assumption that, when the papilla Vateri is closed, the pancreatic secretions flow back into the bile ducts and not - as previously assumed - only bile secretions flow into the pancreas. Due to the entero-hepatic circulation, the enterokinases are in the bile contain that activate the trypsinogen and can thus release TAP. The activated pancreatic enzymes can thus induce inflammation in the gallbladder and bile ducts, which causes local damage to healthy cells. As a result, the inflamed cells can transform into malignant cells, so that malignancies can develop in the bile ducts, the gallbladder and in the area of the papilla Vateri.
- pancreatic carcinoma can also be derived from this new model.
- the basis for this is the phenomenon that the pressure in the bile duct system is usually higher than that in the execution duct of the pancreas. This is due to the stronger muscular system of the biliary tract. If the papilla Vateri is narrowed or occluded, there may be a short-term increase in pressure in the pancreatic duct system, since in this organ with 3000 ml daily about four times the amount of secretion compared to the bile formed in the liver (800 ml / day ) arises. This allows trypsinogen to enter the bile ducts, be activated there and flow back into the pancreas - now in its active form. There it can initially cause proteolytic damage, which can be followed by a transformation of the cells into malignant cells.
- the method according to the invention thus enables a highly specific and sensitive diagnosis of bilio-pancreatic carcinomas. These can be clearly differentiated from other bilio-pancreatic diseases, such as inflammation.
- the teaching according to the invention therefore offers the possibility of early detection of the carcinomas and correspondingly earlier surgical interventions.
- the method according to the invention can also advantageously be used to differentiate bilio-pancreatic carcinomas from other gastrointestinal carcinomas.
- the TAP is preferably quantified by immunological detection in a quantitative solid-phase immunoassay.
- Other biochemical or physical quantitative detection methods are also suitable.
- the patient samples to be examined for their TAP content can be taken from a variety of bodily fluids.
- samples from the blood, bile or urine are suitable. This possibility is among others also due to the low molecular weight of TAP. This can happen, especially in the case of a stasis in the biliary tract, in the bloodstream. It can be filtered renally from the blood and is therefore easily detectable in the urine.
- the patients listed under 7 also suffered from malignant diseases of the digestive system, but the tumor was not localized in the biliopancreatic system.
- gall bladder juice was aspirated perioperatively from surgically removed (ectomized) gall bladders. An 18 G puncture needle was used for this.
- the samples were centrifuged at 3000 G for 10 minutes within the first two hours after collection to separate living cells such as leukocytes or gallbladder epithelial cells.
- the aliquoted samples were kept at -80 ° C until examined.
- the gallbladder samples were previously examined both macroscopically and microscopically for pathological symptoms. Only tumor-free gall bladders were used for the following examinations.
- the TAPKIT test for quantifying the TAP is a quantitative solid-phase enzyme immunoassay which is based on the competitive binding between free and immobilized peptides to an anti-TAP antibody.
- the antibody used has a specificity against the carboxy terminus of the TAP and was generated by immunizing a rabbit with the TAP coupled to thyroglobulin via the amino terminus.
- the TAP contained in the sample is immobilized on a solid phase (plate) via a carrier molecule and incubated with rabbit anti-peptide antibodies with biotinylated IgG and streptavidin-horseradish peroxidase additive.
- the plate is then developed with tetramethylbenzidine (TMB) and the TAP concentration is quantified.
- TMB tetramethylbenzidine
- the specified measuring range is 0.45 - 1000 nM. If the TAP contents in the original samples went beyond this measuring range, the samples were diluted.
- TAP concentrations in the gallbladder juice clearly show higher concentrations for carcinomas of the bilio-pancreatic system.
- Table 1 Mathematical characterization of the different disease groups.
- Table 2 Comparison of the TAP concentrations in the bile juice of patients with benign and malignant bilio-pancreatic diseases
- Fig. 2 Linear distribution of the TAP bile juice concentrations
- Fig. 3 Logarithmic (Iog10) distribution of the TAP bile juice concentrations
- Fig. 4 Distribution of the TAP gallbladder juice concentrations in a linear representation
- Fig. 5 Distribution of the TAP gallbladder juice concentrations in a logarithmic (log 10) representation
- the occurrence of a false positive result can be avoided by increasing the cut-off value - in the present example to 100 nM. This means that no patient with a benign disease would be diagnosed with a malignant tumor, so that the specificity of the method would be 100%.
- the sensitivity of the test is 93.75%, i.e. the patients identified as having a tumor actually have such a malignant tumor. This result surpasses all previously published results of other tumor marker examinations.
- the results show the suitability of the method according to the invention for the differentiation between pancreatitis and pancreatic carcinoma.
- Terada T Nakamuna Y. Expression of Pancreatic Enzymes ( ⁇ -amylase, trypsinogen and lipase) During Human Liver Development and Matuation. Gastroenterol 1995; 108: 1236-1245 12. Ewe K, Karbach U In: Schmidt / Thews (ed.) Human Physiology; Springer-Verlag Heidelberg-London - Paris-Tokyo; 23rd edition 1986
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Hospice & Palliative Care (AREA)
- Gastroenterology & Hepatology (AREA)
- Food Science & Technology (AREA)
- Oncology (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Claims
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10004919A DE10004919A1 (de) | 2000-02-04 | 2000-02-04 | Trypsin aktivierendes Peptid (TAP) als Tumormarker |
DE10004919 | 2000-02-04 | ||
PCT/EP2001/001195 WO2001057536A2 (de) | 2000-02-04 | 2001-02-05 | Verfahren zur diagnose von erkrankungen des bilio-pankreatischen systems |
Publications (1)
Publication Number | Publication Date |
---|---|
EP1256000A2 true EP1256000A2 (de) | 2002-11-13 |
Family
ID=7629812
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP01903698A Withdrawn EP1256000A2 (de) | 2000-02-04 | 2001-02-05 | Verfahren zur diagnose bilio-pankreatischer karzinome |
Country Status (7)
Country | Link |
---|---|
US (1) | US20030138861A1 (de) |
EP (1) | EP1256000A2 (de) |
JP (1) | JP2003527583A (de) |
AU (1) | AU2001231701A1 (de) |
CA (1) | CA2402752A1 (de) |
DE (1) | DE10004919A1 (de) |
WO (1) | WO2001057536A2 (de) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010100862A1 (ja) | 2009-03-05 | 2010-09-10 | 独立行政法人産業技術総合研究所 | 肝内胆管がんの検出、判別方法 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4948723A (en) * | 1987-01-16 | 1990-08-14 | Bioscience International, Inc. | Method of diagnosis and severity-assessment of pancreatic disease |
US5356781A (en) * | 1986-07-28 | 1994-10-18 | Bioscience International, Inc. | Zymogen activation peptides (ZAP) in the diagnosis of disease |
-
2000
- 2000-02-04 DE DE10004919A patent/DE10004919A1/de not_active Withdrawn
-
2001
- 2001-02-05 CA CA002402752A patent/CA2402752A1/en not_active Abandoned
- 2001-02-05 AU AU2001231701A patent/AU2001231701A1/en not_active Abandoned
- 2001-02-05 US US10/181,956 patent/US20030138861A1/en not_active Abandoned
- 2001-02-05 JP JP2001556332A patent/JP2003527583A/ja active Pending
- 2001-02-05 EP EP01903698A patent/EP1256000A2/de not_active Withdrawn
- 2001-02-05 WO PCT/EP2001/001195 patent/WO2001057536A2/de not_active Application Discontinuation
Non-Patent Citations (1)
Title |
---|
See references of WO0157536A3 * |
Also Published As
Publication number | Publication date |
---|---|
US20030138861A1 (en) | 2003-07-24 |
JP2003527583A (ja) | 2003-09-16 |
WO2001057536A3 (de) | 2002-07-11 |
WO2001057536A2 (de) | 2001-08-09 |
DE10004919A1 (de) | 2001-08-09 |
AU2001231701A1 (en) | 2001-08-14 |
CA2402752A1 (en) | 2002-08-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Stevens et al. | A prospective crossover study comparing secretin-stimulated endoscopic and Dreiling tube pancreatic function testing in patients evaluated for chronic pancreatitis | |
Frossard et al. | Usefulness of endoscopic ultrasonography in patients with “idiopathic” acute pancreatitis | |
Altobelli et al. | Colorectal cancer prevention in Europe: burden of disease and status of screening programs | |
JPWO2013038981A1 (ja) | 膵疾患マーカーの検出方法 | |
EP1318403B1 (de) | Verfahren zur Diagnose von Sepsis unter Bestimmung von S100B | |
EP1256000A2 (de) | Verfahren zur diagnose bilio-pankreatischer karzinome | |
Rorat et al. | Post-mortem diagnostics in cases of sepsis. Part 2. Biochemical and morphological examinations | |
Melicow | XANTHIC LESIONS: REPORT OF FOUR CASES, INCLUDING TWO OF XANTHOMATOSIS OF THE KIDNEY | |
DE10101792B4 (de) | Verfahren zum Nachweis von Pankreaskarzinom oder chronischer Pankreatitis und Verwendung von Antikörpern | |
Russell et al. | B-glucuronidase activity of gastric juice in gastric carcinoma. | |
Kumari et al. | Efficacy of lipid ratios and platelet distribution width for assessment of liver fibrosis in patients with non-alcoholic fatty liver disease | |
Lemon | The application of cytologic diagnosis to cancers of the stomach, pancreas and biliary system | |
Symmers | I. Some Comments on the Pathology of the Reticuloses | |
Ando et al. | Hilar lymphadenopathy associated with autoimmune pancreatitis | |
DE102008022609B4 (de) | Verfahren zum Nachweis des Vorkommens von Nierensteinen und/oder Entzündungen der ableitenden Harnwege | |
Teich et al. | The presence of the proteolysis-inducing factor in urine does not predict the malignancy of a pancreatic tumour | |
HISAOKA et al. | Primary actinomycosis in the liver | |
Vanis et al. | Predictive value of endoscopic ultrasound in diagnosis and staging of primary gastric lymphoma | |
Gaia et al. | Duodenal lactoferrin in patients with chronic pancreatitis and gastrointestinal diseases | |
RU2279077C1 (ru) | Способ дифференциальной диагностики форм десквамативного глоссита | |
MARTZLOFF | CANCER OF THE CERVIX UTERI: RECOGNITION OF EARLY MANIFESTATIONS: CLINICAL LECTURE AT SAN FRANCISCO SESSION | |
Malmgren | Studies of circulating cancer cells in cancer patients | |
AT412026B (de) | Verfahren zur diagnose eines zystischen ovarialkarzinoms | |
Al-Taee et al. | Prostatic Specific Antigen and its Correlation with Prostatic Cancer in a Sample of Iraqi Population | |
US5795785A (en) | Method for the diagnosis of human malignant tumors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20020903 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR |
|
AX | Request for extension of the european patent |
Free format text: AL;LT;LV;MK;RO;SI |
|
17Q | First examination report despatched |
Effective date: 20030211 |
|
RTI1 | Title (correction) |
Free format text: METHOD FOR DIAGNOSIS OF BILIO-PANCREATIC CANCERS |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20050801 |